We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Current and future treatment options for polycythemia vera.
- Authors
Griesshammer, Martin; Gisslinger, Heinz; Mesa, Ruben
- Abstract
Patients with polycythemia vera (PV), a myeloproliferative neoplasm characterized by an elevated red blood cell mass, are at high risk of vascular and thrombotic complications and have reduced quality of life due to a substantial symptom burden that includes pruritus, fatigue, constitutional symptoms, microvascular disturbances, and bleeding. Conventional therapeutic options aim at reducing vascular and thrombotic risk, with low-dose aspirin and phlebotomy as first-line recommendations for patients at low risk of thrombotic events and cytoreductive therapy (usually hydroxyurea or interferon alpha) recommended for high-risk patients. However, long-term effective and well-tolerated treatments are still lacking. The discovery of mutations in Janus kinase 2 ( JAK2) as the underlying molecular basis of PV has led to the development of several targeted therapies, including JAK inhibitors, and results from the first phase 3 clinical trial with a JAK inhibitor in PV are now available. Here, we review the current treatment landscape in PV, as well as therapies currently in development.
- Subjects
POLYCYTHEMIA vera; JANUS kinases; PROTEIN-tyrosine kinase inhibitors; INTERFERON alpha; ERYTHROCYTES; GENETIC mutation; THERAPEUTICS
- Publication
Annals of Hematology, 2015, Vol 94, Issue 6, p901
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-015-2357-4